The global pain market is valued at $37 bn. The neuropathic pain market is valued at $5.3 bn across US and EU5 with a Compound Annual Growth Rate (CAGR) of 8% over the past five years.
Read moreDos grupos de investigación estadounidenses han llevado a cabo sendos estudios que demuestran el efecto protector del fármaco GSK744, desarrollado por la multinacional farmacéutica GlaxoSmithKline ...
Read moreThe results indicate that the 12 week treatment was well tolerated and between 87 and 98% of participants in the study achieved HCV RNA less than 25 IU/ml, indicating a sustained virological response ...
Read moreThe increased resistance to existing antibiotics and the lack of new antibiotics in development means that identifying new alternatives to treat bacterial infections is crucial
Read more“This is the most important discovery made on mutations in cholangiocarcinoma and will radically change the treatment of this disease”, explains Dr. Llovet.
Read moreResearchers in Barcelona discover more potential candidates on the route to tailored, photo-switchable therapies by disproving design limitation
Read moreThe expected end-result will be the obtaining of an optimal formulation and a route of administration of the compound for its use as a drug in patients. This will allow carrying out the regulatory pre...
Read moreLos resultados demuestran que la eribulina es un fármaco eficaz para usar como quimioterapia con un solo fármaco en pacientes con cáncer de mama avanzado y tratadas previamente con quimioterapia, q...
Read moreThe COMBACTE-MAGNET project will investigate a new approach for preventing respiratory infections in ICU patients and new treatment options for patients with life-threatening infections due to MDR-GNB...
Read moreThe patent of the molecule was recently granted by the United States to the Spanish company Inurrieta Consultoria Integral and is currently being presented to different pharmaceutical laboratories
Read moreLos compuestos que presentan actividad biológica en estos ensayos podrían representar una futura solución terapéutica para enfermedades relacionadas con la alteración de los neurotransmisores nor...
Read moreMols is a SaaS platform breaks the two main barriers faced by computational drug design: implementation costs - it eliminates investments in servers and software licensing- and the training of the tea...
Read more